Filter
72
Filtered Results: 72
Text search:
DNDi
-
Drugs
for
neglected
diseases
initiative
Featured
Recommendations
8
New Publications
4
Language
Document type
Studies & Reports
30
No document type
12
Manuals
6
Strategic & Response Plan
6
Resource Platforms
5
Fact sheets
4
Guidelines
3
Videos
3
Brochures
2
Infographics
1
Countries / Regions
Global
8
Latin America and the Carribbean
7
Colombia
4
Kenya
2
Africa
2
West and Central Africa
2
East and Southern Africa
2
Ethiopia
2
Asia
1
Southern Africa
1
Uganda
1
Brazil
1
India
1
Authors & Publishers
Publication Years
Category
Countries
14
Clinical Guidelines
9
Pharmacy & Technologies
3
Public Health
1
Toolboxes
NTDs
50
HIV
3
Global Health Education
3
COVID-19
2
Pharmacy
2
TB
1
NCDs
1
AMR
1
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease
(CD). T. cruzi is transmitted by triatomine insects, congenitally, through uncontrolled blood donations and organ transplants,
and via consumption of food or drink contaminated by triatomi...
Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach...
The Lancet Infectious Disease Volume 25, Issue 2e77-e85February 2025
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 117: e200460, 2022
Integrating the multiple dimensions of the problem into a coherent approach adapted to field realities and needs represents an immense challenge, but the payoff is more effective and sustainable experiences, with higher social awareness...
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th...
PLOS Neglected Tropical Diseases 18(5): e0012091. https://doi.org/10.1371/journal.pntd.0012091
J Glob Health Sci. 2020 Jun;2(1):e3. A group of enzootic and zoonotic protozoan infections, the leishmaniases constitute among the most severely neglected tropical diseases (NTDs) and are found in all continents except Oceania. Representing the most common infectious diseases, NTDs comprise an open-...
Front. Trop. Dis. , 09 May 2023 Sec. Neglected Tropical Diseases Volume 4 - 2023 | https://doi.org/10.3389/fitd.2023.1087003
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...
On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO and in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration for Infectious Dis...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...
Lessons from the STEP-TB Project.
Accessed November 2017.
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
The Lancet Volume 5, Issue 10100972October 2024 Chagas Disease Serie 3
Technology landscape
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...
Meeting Report
27–30 June 2017 Manila, Philippines
Rreport of a WHO Consultative Meeting Kolkata India 2012
